Biography
Dr. David Browning is a board-certified ophthalmologist who focuses on vitreoretinal diseases and surgery, macular degeneration, and the retina in the Charlotte, NC and Concord, NC areas. He is board-certified by the American Board of Ophthalmology. He has authored and co-authored more than 120 papers in peer-reviewed journals and has written and edited three textbooks.
Dr. Browning practices in our SouthPark (6035 Fairview
Road, Charlotte, NC) and Concord (645 Amalia Street NE, Concord,
NC) offices. To make an appointment with him, call 704-295-3000. You can also
request an appointment online or through myCEENTAchart.
Education & Fellowship
Undergraduate
Harvard University, 1975
PhD and Medical
Duke University, 1980 and 1981, respectively
Internship
Duke University Medical Center, 1982
Residency
Ophthalmology, Duke Eye Center, 1985
Fellowship
Vitreoretinal diseases, Bascom Palmer Eye Institute, University of Miami, 1986
Associations & Memberships
Board Certified by:
- American Board of Ophthalmology
Member of:
- American Board of Ophthalmology, Examiner and Mentor Examiner
- American Academy of Ophthalmology, Fellow
- American Ophthalmological Society
- Executive Editor of the American Journal of Ophthalmology and Editorial Board member of Retina
Community Involvement
Dr. Browning has given continuing education talks including:
"Melanoma, Mecklenburg... and More"
"OCT Omnibus - Cases That Will Make You Sharper in Clinic"
"Screening for Hydroxychloroquine Retinopathy in 2018"
"Retinal Cases with a Point"
Research
Dr. Browning has authored and co-authored more than 120 papers in peer-reviewed journals including: Diabetic macular edema: Evidence-based management.
Browning DJ, Stewart MW, Lee C. Indian J Ophthalmol. 2018 Dec;66(12):1736-1750. doi: 10.4103/ijo.IJO_1240_18.
He is the author and editor of three textbooks including: Hydroxychloroquine and Chloroquine Retinopathy, published in 2014.
He has directed/participated in more than 35 clinical research trials and is currently enrolling patients in trials for treatments of diabetic retinopathy and vitreomacular traction syndrome.
